Publications by authors named "C Swallow"
Purpose: Retroperitoneal sarcomas (RPS) are rare, heterogeneous tumours. Treatment recommendations are mainly derived from cohorts treated at reference centres. The applicability of data from cancer registries (CR) is controversial.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates abdominal venous leiomyosarcoma (AV-LMS), focusing on its origins from veins associated with the sex-hormone drainage pathway (SHDP).
- A retrospective analysis of imaging from 155 patients with confirmed non-uterine abdominal/pelvic LMS revealed that more than half of the tumors originated from venous structures, particularly those linked to the SHDP, including adrenal and ovarian veins.
- Key findings indicate that tumors from the SHDP are prevalent and may lead to a lower risk of distant metastases at diagnosis, with tumor size and SHDP origin being critical factors in predicting metastasis risk.
Background: In Western countries, the current standard of care for resectable gastric cancer is perioperative chemotherapy. Preoperative chemoradiotherapy has been considered, but data are limited regarding this treatment as compared with perioperative chemotherapy alone.
Methods: We conducted an international, phase 3 trial in which patients with resectable adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to receive preoperative chemoradiotherapy plus perioperative chemotherapy or perioperative chemotherapy alone (control).
Article Synopsis
- Gastric adenocarcinoma (GCa) has a high fatality rate in Europe and North America, largely due to late-stage diagnoses, despite advancements in treatment options.
- There is significant interest in FAM46C, a protein linked to tumor suppression, as its depletion is commonly observed in GCa patients and is associated with cancer recurrence and mortality.
- Research is exploring FAM46C as a potential biomarker and therapeutic target for GCa progression, with Norcantharidin emerging as a promising compound to restore FAM46C levels currently in phase one clinical trials.
Background: The incidence of esophageal and gastric carcinoma (GEC) in elderly patients is increasing, yet patients ≥75 years have historically been underrepresented in clinical trials. We sought to investigate palliative chemotherapy administration patterns and survival outcomes in older adults.
Materials And Methods: A retrospective analysis identified patients aged 65-74 (young-old) and ≥75 years (older-old) diagnosed with advanced GEC.